Evaluating health-related quality of life (HRQoL) in Iraqi adult and pediatric patients with beta-thalassemia major using two different iron chelation therapies
العناوين الأخرى
تقييم جودة الحياة النوعية لمرضى الثلاسيميا الكبرى البالغين و الأطفال في العراق الذين يستخدمون علاجين مختلفين لطاردات الحديد
المؤلفون المشاركون
Shawkat, Ali Jalal
Juwayd, Ahmad Hamid
Awwad, Ghadah Marzuq
المصدر
Iraqi Journal of Pharmaceutical Sciences
العدد
المجلد 28، العدد 1 (30 يونيو/حزيران 2019)، ص ص. 44-52، 9ص.
الناشر
تاريخ النشر
2019-06-30
دولة النشر
العراق
عدد الصفحات
9
التخصصات الرئيسية
الملخص EN
Beta Thalassemia major (β-TM) is a common inherited blood disorder in Iraq.
Iron overload is caused by repeated blood transfusion; which may result in severe complications.
Patients with β-TM require lifelong adherence to a burdensome medical regimen which could potentially impact their ' quality of life (QoL).
Hence, it is of utmost importance to pay a great attention to their Health-Related Quality of Life (HRQoL).
A cross-sectional study was performed to evaluate health-related quality of life in both adult and pediatric patients using Deferoxamine (DFO) or Deferasirox (DFX) iron chelation therapies (ICTs) and to assess different factors affecting their elated quality of life.
Two instruments were used to evaluate quality of life; the WHOQOL-BREF questionnaire was used to evaluate quality of life in adults (DFO group and DFX group), and PedsQL was used to evaluate quality of life in pediatrics (DFO group and DFX group).
Several variables were assessed for correlation with quality of life domains.
In adults patients; Health-Related Quality of Life (HRQoL) components were significantly lower in patients receiving Deferoxamine (DFO).
In pediatric patients, only physical functioning score was significantly lower in Deferoxamine(DFO) receiving patients, the rest of the variables show no statistical differences.
Pediatrics have slightly better quality of life (QoL) and lower complications in comparison to adults.
Thalassemia impairs quality of life (QoL) in all patients significantly.
Improving quality of life (QoL) is achieved by better control of iron overload, iron chelation therapies (ICTs) adverse effects, and complications
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Shawkat, Ali Jalal& Juwayd, Ahmad Hamid& Awwad, Ghadah Marzuq. 2019. Evaluating health-related quality of life (HRQoL) in Iraqi adult and pediatric patients with beta-thalassemia major using two different iron chelation therapies. Iraqi Journal of Pharmaceutical Sciences،Vol. 28, no. 1, pp.44-52.
https://search.emarefa.net/detail/BIM-894639
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Shawkat, Ali Jalal…[et al.]. Evaluating health-related quality of life (HRQoL) in Iraqi adult and pediatric patients with beta-thalassemia major using two different iron chelation therapies. Iraqi Journal of Pharmaceutical Sciences Vol. 28, no. 1 (2019), pp.44-52.
https://search.emarefa.net/detail/BIM-894639
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Shawkat, Ali Jalal& Juwayd, Ahmad Hamid& Awwad, Ghadah Marzuq. Evaluating health-related quality of life (HRQoL) in Iraqi adult and pediatric patients with beta-thalassemia major using two different iron chelation therapies. Iraqi Journal of Pharmaceutical Sciences. 2019. Vol. 28, no. 1, pp.44-52.
https://search.emarefa.net/detail/BIM-894639
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references : p. 50-52
رقم السجل
BIM-894639
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر